The Vietnamese government is looking to boost its share of the world's clinical research market, signing a deal with CRO giant Quintiles to get the ball rolling.
Eli Lilly and the nonprofit Project A.L.S. are teaming up to boost the pipeline of potential drugs for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig' disease.
Combination cancer therapies are all the rage these days in the oncology field. Now two of the giant players in the cancer R&D arena have decided to match their top prospects to see if they can make a bigger impact on melanoma.
Unilife took another big step this week, signing a long-term contract agreement with generics maker Hikma Pharmaceuticals to use Unilife's injectable technology and netting up to $40 million in the process.
With the success of Erbitux and its patient-steering companion diagnostic fresh in mind, Qiagen and Eli Lilly have struck up their third partnership, reuniting to match genomic knowhow with drug development expertise.
Long-troubled biotech Cell Therapeutics has landed a big-name partner for its Phase III myelofibrosis drug, convincing Baxter to shell out $60 million upfront for a cut of pacritinib.
Merck KGaA is strengthening its embrace of China's BeiGene, adding a second cancer drug development alliance to their collaboration along with an extra $232 million package of new milestone payments.
Fresh off a $46 million funding round, Germany's immatics has inked a deal to collaborate with Roche on cancer therapies, signing an end-to-end agreement that could bring in more than $1 billion in milestones.
Injectable drug delivery specialist Unilife joined forces with AstraZeneca's MedImmune this week to use Unilife's wearable devices with MedImmune's line of large molecules, putting both companies on the leading edge of a potentially profitable market.
Israel's Sensible Medical has picked up a reported $20 million to fund development of its noninvasive lung fluid monitor, closing a round led by global device giant Boston Scientific.